ArticleIranian journal of biotechnology2026
Zinc Finger Protein 706 Gene a Potential Diagnostic and Therapeutic Target in Hepatocellular Carcinoma: Implications for Cancer Biotechnology.
Article in Iranian journal of biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zinc finger proteins, particularly Zinc Finger Protein 706 (ZNF706), have been implicated in various cancers, yet their functional and clinical significance in hepatocellular carcinoma (HCC) remains unclear. Identifying novel biomarkers and therapeutic targets is essential for improving HCC diagnosis and treatment. Objectives: To investigate the functional role of ZNF706 in HCC and evaluate its potential as a diagnostic and therapeutic target with biotechnological applications. Materials and Methods: Bioinformatic analyses were performed using clinical and transcriptomic data from TCGA and GTEx databases to assess ZNF706 expression and its correlation with clinicopathological features and patient prognosis. Quantitative PCR and Western blotting validated ZNF706 expression in liver epithelial and HCC cell lines. Functional assays, including CCK-8, flow cytometry, and Transwell migration/invasion assays, were conducted following ZNF706 knockdown. Results: ZNF706 was significantly overexpressed in HCC tissues and cell lines compared to normal controls. High ZNF706 expression correlated with advanced TNM stage, pathological stage, and poor survival outcomes. Knockdown of ZNF706 inhibited proliferation, migration, and invasion, and increased apoptosis in HCC cells. ROC analysis demonstrated high diagnostic accuracy (AUC > 0.90) for ZNF706 in distinguishing HCC and predicting prognosis. Conclusions: ZNF706 is a promising biomarker for HCC diagnosis and prognosis and represents a potential therapeutic target for biotechnological intervention. These findings support the development of ZNF706-based diagnostic assays and targeted therapies for improved management of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.